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Abstract
Background: Cervical cancer is the second most common cancer in women worldwide. NK and
cytotoxic T cells play an important role in the elimination of virus-infected and tumor cells through
NKG2D activating receptors, which can promote the lysis of target cells by binding to the major
histocompatibility complex class I-related chain A (MICA) proteins. Increased serum levels of MICA
have been found in patients with epithelial tumors. The aim of this study was to compare the levels
of soluble MICA (sMICA) and NKG2D-expressing NK and T cells in blood samples from patients
with cervical cancer or precursor lesions with those from healthy donors.
Methods: Peripheral blood with or without heparin was collected to obtain mononuclear cells or
sera, respectively. Serum sMICA levels were measured by ELISA and NKG2D-expressing immune
cells were analyzed by flow cytometry. Also, a correlation analysis was performed to associate
sMICA levels with either NKG2D expression or with the stage of the lesion.
Results: Significant amounts of sMICA were detected in sera from nearly all patients. We found a
decrease in the number of NKG2D-expressing NK and T cells in both cervical cancer and lesion
groups when compared to healthy donors. Pearson analysis showed a negative correlation between
sMICA and NKG2D-expressing T cells; however, we did not find a significant correlation when the
analysis was applied to sMICA and NKG2D expression on NK cells.
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Conclusion: Our results show for the first time that high sMICA levels are found in sera from
patients with both cervical cancer and precursor lesions when compared with healthy donors. We
also observed a diminution in the number of NKG2D-expressing NK and T cells in the patient
samples; however, a significant negative correlation between sMICA and NKG2D expression was
only seen in T cells.
Background
Cervical cancer is the second most common malignant
tumor in women worldwide, and the most common
tumor in developing countries including Mexico, the site
of this study [1-3]. Infection with high-risk human papil-
loma virus (HPV) is considered the major etiological fac-
tor of HPV-related premalignant lesions and cervical
cancer [4-7]. Virtually all cervical carcinoma patients
(99.7%) have shown to be HPV-DNA carriers [8].
Although HPV prevalence is very common in sexually
active women [9], the infection in the majority of cases is
transient, clearing in a short period of time without pro-
gression to clinical lesions [10-12]. In a minority of cases,
HPV presence is established as a persistent infection. It is
thought that viral persistence leads to progression from
low-grade squamous intraepithelial lesions (LSIL) to
high-grade squamous intraepithelial lesions (HSIL) and
eventually to invasive carcinoma [13-16]. The progression
of the lesions may involve an adverse tumor environment,
wherein the mucosal immune response may be unable to
eradicate malignant cells.
The innate immune response is considered to be the first
line of defense at mucosal surfaces. NK cells are an impor-
tant arm of the innate immune system specialized for kill-
ing virus-infected and tumor cells [17]. The activity of NK
cells is tightly regulated by a complex balance of inhibi-
tory and activating receptors [18]. NKG2D is a C-type lec-
tin-like activating receptor encoded within the NK gene
complex on human chromosome 12 [19]. NKG2D is
expressed in almost all NK cells and a variety of T cell sub-
sets such as CD8+ T cells [20]. NKG2D can promote tumor
lysis by binding to a recently identified family of cell sur-
face ligands encoded by the MHC class I chain-related
(MIC) genes [21-23]. MIC proteins are a novel family of
non-classical MHC class I molecules. The MIC family
includes MICA, which is a highly polymorphic functional
cell-surface protein [24]. Similar to classical HLA class I
molecules, MICA also contains three extracellular
domains (α1-α3); however, MICA neither associates with
β2-microglobulin nor binds antigen peptides. Under nor-
mal physiological conditions, MICA expression is almost
restricted to the gastrointestinal epithelium [25,26]; nev-
ertheless, MICA is overexpressed in several epithelial
tumors [27-30]. This finding has led to the proposal that
MICA is a stress cell marker in nascent epithelial tumors
[26].
Available evidence suggests that NKG2D engagement by
MICA induces proliferation, survival, and, cytotoxic activ-
ity in NK cells [31,32]. Consequently, NKG2D/MICA
interaction may represent an important activation path-
way to trigger the immune attack against tumor cells
[30,33]. However, it has been demonstrated that MICA
shedding from tumor cell surface occurs in a variety of
malignant epithelial tumors, including advanced hepato-
cellular carcinoma, colon, prostate, renal, and breast can-
cer, as well as hematopoietic tumors [34-38].
Accumulation of sMICA in serum may lead to the down-
modulation of NKG2D through the facilitation of
NKG2D internalization and lysosomal degradation. This
strategy has been proposed to be a novel mechanism used
by cancer cells to evade the tumor immunosurveillance
[39].
In this study, we formulated the hypothesis that sMICA
levels increase concomitantly with the natural history of
cervical cancer in the progression from intraepithelial pre-
cursor lesion to invasive cancer. To address this assertion,
we compared the sMICA levels and the number of
NKG2D-expressing NK and T cells in blood samples from
patients with cervical cancer or precursor lesions with
those from healthy donors. We also performed a correla-
tion analysis to explore a relationship between sMICA lev-
els and NKG2D expression. Furthermore, we associated
sMICA levels with the stage of the lesion.
Methods
Patients
In accordance with the FIGO (International Federation of
Gynecology and Obstetrics) System of Clinical Staging
[40,41], we included 10 patients with invasive squamous
cell carcinoma of the uterine cervix and 17 patients with
squamous intraepithelial lesion, which were classified as
high-grade squamous intraepithelial lesion (HSIL) or
low-grade squamous intraepithelial lesion (LSIL) follow-
ing the 2001 Bethesda System for reporting cervical or
vaginal cytologic diagnoses [42,43]. All patients enrolled
in the study were first subjected to colposcopic evaluation.
Ten age/gender matched healthy donors were also
included as control group. All patients were attended at
the Oncology and Gynecology Department, Hospital
Civil de Guadalajara, Mexico.BMC Cancer 2008, 8:16 http://www.biomedcentral.com/1471-2407/8/16
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Peripheral blood (PB) samples were taken after written
informed consent was obtained from all patients (LSIL,
HSIL, and cervical cancer) and healthy donors. Samples
were collected in heparinized tubes to separate peripheral
blood mononuclear cells (PBMC). PB was also obtained
without heparin in order to separate serum, which was
stored at -20°C until use.
Ethical considerations
The present study was approved by the Research Ethics
Committee in Biomedical Sciences (Universidad de
Guadalajara, Guadalajara, Jalisco, Mexico and Hospital
Civil de Guadalajara, OPD, Guadalajara, Jalisco, Mexico.
Trial reference: CSIM 200-22, 20000302032), in accord-
ance with the guidelines of the Mexican Official Standard
(Norma Oficial Mexicana NOM) and the World Medical
Association Declaration of Helsinki (adopted by the 52nd
WMA General Assembly, Edinburgh, Scotland, October
2000).
Quantification of sMICA in serum
MICA ELISA kit (Immatics Biotechnologies, Tübingen,
Germany) was used to detect sMICA in serum samples,
according with the manufacturer protocol. Briefly, after
covering the 96 well flat-bottom plates with capture anti-
MICA mAb, standard serial dilutions and serum samples
were added to each well. Detection anti-MICA mAb was
added to the wells. HRP-conjugated anti-mouse Ab
(Southern Biotechnologies, Birmingham, AL, USA) was
added and color was developed using tetramethylbenzi-
dine system (KPL, Gaithersburg, MD, USA). Absorbance
values (at A450) by duplicate were plotted against dilu-
tions and expressed as pg/mL (normalized to log10).
NKG2D expression on NK and T cells
Surface NKG2D expression was evaluated by flow cytom-
etry. Briefly, PBMC were obtained by Ficoll-Hypaque den-
sity gradient centrifugation. After isolation, PBMC were
adjusted at 8 × 105 cells/mL and incubated with mouse
anti-NKG2D primary mAb (kindly donated by Professor
Alessandro Moretta, University of Genova, Italy) for 30
min at 4°C. Cells were washed with PBS and incubated
with goat anti-mouse IgG FITC-conjugate as a secondary
reagent for 30 min at 4°C in the dark. Afterward, cells
were washed and incubated with PE-conjugated anti-
CD56, and PC5-conjugated anti-CD3 mAb; matching iso-
type controls were also included. Finally, cells were fixed
with 0.5% paraformaldehyde solution. A three-color anal-
ysis on an EPICS XL-MCL Flow Cytometer (Beckman
Coulter, Krefeld, Germany) was used to determine the
NKG2D expression on CD56+CD3- and CD56-CD3+ pop-
ulations.
Statistical analysis
Statistical analysis of all data was done using SPSS soft-
ware version 10 (Chicago, IL, USA). The sMICA levels and
percentages of NKG2D-expressing NK and T cells were
expressed as mean ± SD. Statistical comparisons among
different groups were performed using a non-parametric
test (Mann-Whitney test). Pearson analysis was performed
to correlate sMICA levels with NKG2D expression and
Spearman analysis was performed to correlate sMICA lev-
els with the stage of the lesion. Additionally, a multivari-
ate regression analysis was achieved to evaluate whether
sMICA and NKG2D expression act in concert during the
cervical cancer progression. For this analysis we used the
method "forward stepwise" in which we added the inde-
pendent variables (sMICA and NKG2D expression) one
by one. A 95% confidence interval (p < 0.05) was consid-
ered statistically significant.
Results
Ten patients with established histopathological diagnosis
of uterine cervix invasive squamous cell carcinoma were
enrolled in this study. Additionally, a group of 17 patients
with squamous intraepithelial lesions was composed of 7
individuals diagnosed as high-grade and 10 individuals
diagnosed as low grade. We also included a control group
matched in age/gender as shown in Table 1. Clinical and
laboratory parameters confirmed that patients and con-
trols did not have any autoimmune or blood disorder that
could alter our study variables (sMICA level and NKG2D
expression).
sMICA levels are preferentially augmented in patients with 
cervical cancer and precursor lesions
We investigated the sMICA level in sera from cervical car-
cinoma patients and SIL patients (including both high-
grade and low-grade lesions). Additionally, we also tested
sMICA in healthy individuals. In order to normalize the
sMICA values, we converted the data (expressed as pg/mL)
to log10. As shown in Figure 1, we found significantly
higher sMICA levels in patients with cervical cancer or pre-
cursor lesions when compared with healthy donors
(Mann-Whitney test, p < 0.005 in LSIL, p < 0.030 in HSIL,
Table 1: Patient characteristics
Study group
Age (years)
n
Healthy donors 10 27–52
Median age = 38.4
SIL LSIL 10 26–50
Median age = 36.6
HSIL 7 23–49
Median age = 35.0
Carcinoma 10 29–69
Median age = 45.4BMC Cancer 2008, 8:16 http://www.biomedcentral.com/1471-2407/8/16
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and p < 0.001 in cancer group). Interestingly, the majority
of healthy individuals showed almost undetectable
sMICA level (lower than 1 pg/mL). In contrast, measura-
ble sMICA level was found in patients with cervical cancer
and precursor lesions. The highest sMICA level was found
in the cancer group (4.56 pg/mL). We also examined a
potential relationship between sMICA level and the stage
of the lesion. Spearman correlation showed that sMICA
level was significantly positively correlated with the sever-
ity of the lesion (Rho = 0.519; p < 0.001).
Reduced numbers of NKG2D-expressing NK and T cells in 
patients with cervical cancer and precursor lesions
NKG2D plays an important role in the immune recogni-
tion of tumor targets after engagement by MICA mole-
cules [31,32]. Nevertheless, there is evidence showing that
circulating sMICA interferes with NKG2D expression on
NK and T cells [39]. Owing to the observed increase in the
sMICA levels detected in sera from patients with cervical
cancer and those with precursor lesions, we investigated
expression of the NKG2D receptor on peripheral NK and
T cells. First, we evaluated the percentage of NK and T cells
in all patients and healthy donors. The results fell into the
normal range in all groups, with a non-significant drop in
cancer group (data not shown). In order to determine
NKG2D expression on NK cells, we gated the CD56+CD3-
population. As shown in Figure 2A and Table 2, we found
the following results: 50.40% of the gated population was
NKG2D-positive in the control group, 28.57% in LSIL,
40.90% in HSIL and 27.49% in cancer group. Statistical
comparison between the cancer and control groups
revealed a significant difference (p < 0.034).
We also analyzed the CD56-CD3+ population to deter-
mine NKG2D expression in T cells. We observed a
decrease in the number of NKG2D-expressing T cells con-
cordant with the severity of the lesion, as can be observed
in Figure 2B and Table 2. The control group showed
24.80% of the gated population to be NKG2D-positive
cells. In contrast, LSIL, HSIL, and cancer groups showed
NKG2D positive percentages of 15.74, 12.20, and 8.28,
respectively. Statistical analysis revealed a significant dif-
ference in both precursor lesion and cancer groups when
compared to healthy individuals (p < 0.041, p < 0.011,
Table 2: NKG2D-expressing NK and T cells
Percentage of NKG2D-expressing cells
Subjects CD56+CD3- CD56-CD3+
Mean
± SD
Min Max p Mean
 ± SD
Min Max p
Healthy 50.40 ±
20.78
21.44 83.84 24.80 ±
7.67
17.30 40.20
LSIL 28.57 ±
1.36
3.60 78.40 0.010 15.74 ±
6.91
6.40 28.50 0.041
HSIL 40.90 ±
5.67
2.70 88.10 0.495 12.20 ±
7.49
2.40 22.80 0.011
Invasive carcinoma 27.49 ±
9.62
0.50 82.90 0.034 8.28 ± 
0.25
0.10 29.60 0.005
p represents the value obtained of comparing LSIL, HSIL, and carcinoma subjects vs healthy subjects
Serum sMICA is elevated in cervical cancer patients Figure 1
Serum sMICA is elevated in cervical cancer patients. sMICA 
was determined by using ELISA assay. Short horizontal lines 
indicate the median value (pg/mL normalized to log10) in each 
group. Statistical analysis among all groups was performed by 
Mann-Whitney test.
Log
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(pg/mL)
10
Subjects
Healthy
1
2
3
4
5
LSIL HSIL Carcinoma
p<0.005
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and p < 0.005 to LSIL, HSIL, and cancer groups, respec-
tively).
Circulating sMICA can reduce the number of NKG2D-
expressing T cells
It has been reported that sMICA in serum from patients
with cancer induces down-modulation of surface NKG2D
expression [39]. For this reason, we investigated a poten-
tial correlation between sMICA levels and the percentage
of NKG2D-expressing NK and T cells. As shown in Figure
3, sMICA levels were negatively correlated with the
number of NKG2D-expressing T cells (r = -0.359; p  <
0.015). In contrast, we did not observe any significant cor-
relation between sMICA level and NKG2D-expressing NK
cells (data not shown). It is important to mention that
despite the lack of statistical correlation, we observed a
substantial decrease of NKG2D-expressing NK cells in
more than a half of the analyzed patients with cervical
cancer. Figure 4 shows representative histograms and dot
plots of NKG2D-expressing NK and T cells in all groups.
We used a multivariate regression analysis to determine
whether increasing sMICA levels and decreasing NKG2D
expression on T cells could act in concert to predict the
progression of the lesion advancing toward cancer. The
results derived from that analysis (Table 3) show that both
categories (sMICA level and NKG2D) were significantly
strongly related with the progression of the lesion (R2 =
0.467; p < 0.001). The importance of these results is that
R2 explains (46.7%) of the variation in the progression
toward cancer.
Discussion
Recent reports have revealed a new tumor evasion strategy
involving MICA release from malignant cell surface in dif-
ferent human tumors [34-37]. In this study we found sig-
nificant sMICA levels in patients with cervical cancer.
Proteolytic shedding has been proposed as the key mech-
anism by which MICA is released from the cell surface,
similar to the cleavage occurring with other membrane-
bound proteins. By using different protease inhibitors, it
was elucidated that metalloproteinases were responsible
for the cleavage of the MICA α1α2α3 extracellular
domain from the cell surface in several tumor lines [44].
This finding may have implications to cervical cancer as
previous data in our laboratory have shown extensive
NKG2D-expressing immune cells are decreased in patients with cervical cancer and precursor lesions Figure 2
NKG2D-expressing immune cells are decreased in patients with cervical cancer and precursor lesions. Three color flow 
cytometry analysis to detect CD3, CD56 and NKG2D was carried out on PBMC to determine the percentage of NKG2D-pos-
itive cells. A) NKG2D-expressing NK cells (CD56+CD3- population); B) NKG2D-expressing T cells (CD56-CD3+ population). 
The box plots represent each study group. Medians are represented as thick horizontal lines, 25th and 75th percentiles as boxes 
and 10th and 90th percentiles as whiskers. *Extreme values.
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metalloproteinase activity in cervical tissue extracts from
patients with cervical cancer and precursor lesions [45].
This suggests that metalloproteinases, aside from playing
an important role in invasion, metastasis, and angiogen-
esis processes, may also have a role in allowing MICA
shedding tumor cells to evade immune attack. However,
we cannot discard the possibility that other different pro-
teases are also participating in the cleavage of MICA as has
been recently reported by Kaiser et al. In that report, the
authors demonstrated that MICA shedding was facilitated
by a disufide-isomerase interacting directly with MICA α3
[46]. Thus, it appears that different enzymes could be ena-
bling tumor cells to escape from the immune attack. Since
in this study we did not examine the relevance of the pro-
teolytic activity, it will be of particular importance to char-
acterize the enzymatic activity with respect to cell surface
MICA shedding in cervical cancer.
We observed higher levels of sMICA in patients with low-
grade intraepithelial lesions in comparison with healthy
individuals; these levels increased in accordance with can-
cer progression. This finding is in agreement with recent
results obtained by Wu et al., who detected elevated
amounts of sMICA in patients with prostate cancer [36].
Moreover, significantly higher levels were seen in patients
with more advanced diseases, suggesting that the MICA
shedding may contribute to prostate cancer progression
Thus, consistent with Wu et al., we could speculate that
high levels of circulating sMICA that we observed may be
contributing to the immune tolerance observed in
patients with cervical cancer. However, functional experi-
ments to elucidate the actual relevance of MICA/NKG2D
pathway in cervical cancer will be necessary.
Different studies have proven the down-modulation of
HLA class I expression during cervical cancer progression
[47,48]. Hence, it is feasible to assume that NK cells may
represent an important immune defense against cervical
cancer. Different activating receptors confer to NK cells
the capacity to kill virus-infected or tumor cells [49,50];
one of these receptors is represented by NKG2D, which
can recognize different ligands including MICA mole-
cules; thus, NKG2D could have a significant role in anti-
tumor immune response [21-23].
Recently, Doubrovina et al., have established that MICA in
serum from patients with colon adenocarcinoma down-
modulates NKG2D expression on NK cells via its internal-
ization and subsequent lysosomal degradation [35].
Importantly, we observed a reduction of NKG2D-express-
ing NK cells in patients with cervical cancer and precursor
lesions; however, we did not find a significant statistical
correlation between sMICA and lower NKG2D expression
on these cells. These results indicate that additional fac-
tors could be also affecting the surface NKG2D expres-
sion. Lee et al., have provided evidence showing that TGF-
β1 present in plasma of lung and colorectal cancer
patients impairs NK cell activity via NKG2D down-modu-
lation [51]. Using a technology to silence TGF-β1 and -β2
genes in malignant glioma cells, Friese et al. revealed that
these tumor cells did not down-modulate the NKG2D
expression on NKL cells (a NK cell line); moreover, strong
surface MICA expression on tumor cells was also observed
when they blocked the TGF-β production promoting a
strong recognition by immune cells [52]; these results
support the key role of TGF-β in the MICA/NKG2D path-
way. It is well known that this cytokine is largely produced
by many tumor cells and it is also common in cervical
squamous intraepithelial lesions [53]. For instance, it has
been shown that HPV-11 transformed human tissue over-
expresses TGF-β1 [54] and benign cervical lesions, partic-
ularly, have been associated with HPV-6 or -11.
It has been recently observed that NKp44, another impor-
tant receptor confined only to activated NK cells, becomes
down-modulated on NK cells from both healthy donors
and patients with cancer upon exposure to sMICA-con-
taining serum [35]. Taking into account that both NKG2D
and NKp44 on the cell surface may be down-modulated
by sMICA, it is viable to consider that circulating sMICA
could be affecting the integration of different crucial trig-
gering signals in NK cells. Collectively, these alterations
sMICA levels and the number of NKG2D-expressing T cells  are negatively correlated Figure 3
sMICA levels and the number of NKG2D-expressing T cells 
are negatively correlated. Correlation analysis was done 
using the Pearson test. Values are normalized as log10.
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may be contributing to the incomplete NK cell-mediated
cytotoxic function in patients with cancer.
NKG2D expression is not only confined to NK cells, but it
is also expressed on CD8+ cytotoxic T cells, where this
receptor confers co-stimulatory signals [55]. Moreover,
NKG2D expression has also been described in a subset of
CD4+ T cells from patients with some inflammatory dis-
eases [56]. For this reason, we also evaluated surface
NKG2D expression on T cells and analyzed its correlation
with sMICA level. Despite finding a statistically significant
correlation between sMICA level and NKG2D-expression,
The number of NKG2D-expressing NK and T cells diminishes during cervical cancer progression Figure 4
The number of NKG2D-expressing NK and T cells diminishes during cervical cancer progression. NKG2D expression was 
measured using flow cytometry while gating on CD56+CD3- (NK cell) and CD56-CD3+ (T cell) populations. The histograms 
and dot plots show the results obtained from a representative individual of each group. The same tendency is observed in both 
NK and T cells (filled curve: isotype control Ab, open curve: anti-NKG2D).
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our analysis only showed a weak correlation, which sug-
gests the existence of additional factors that, in concert
with sMICA, could promote the NKG2D down-modula-
tion; one of such factors could be TGF-β1 as previously
mentioned. In contrast to the several reports supporting
the role of sMICA in the NKG2D down-modulation [39],
there is a recent report by Osaki et al., which showed that
sMICA levels were not different between gastric cancer
patients and normal controls, indicating that sMICA was
not responsible for inducing the NKG2D down-modula-
tion on CD8+ T cells from those patients. However, tran-
swell experiments demonstrated that direct contact
between CD8+ T cells and MICA-expressing tumor cells
caused NKG2D down-modulation, indicating that surface
MICA was responsible for that defect [57]. Independent of
its form (sMICA or membrane MICA), it is clear that this
molecule promotes, in part at least, the NKG2D down-
modulation in immune cells. Since in this study we only
used an anti-CD3 antibody, we were not able to distin-
guish between NKG2D-expressing CD8+ or CD4+ T cells;
thus, this methodological flaw could also explain the
weak correlation seen between sMICA level and NKG2D-
expressing T cells. Therefore, the analysis to distinguish
CD8+ or CD4+ T cells would have been more interesting
and meaningful that our present results, which were con-
fined to the total T cell population. Future studies are
planned to identify the actual T cell population in which
cell surface NKG2D is being affected. Consequently, it will
be possible to discern if specific T cell lineages fail to be
fully activated in patients with HPV-associated cervical
lesions.
In this study we have demonstrated a reduction in the
number of NKG2D-expressing immune cells. At the
moment, we do not know the meaning of this finding;
however, we consider that this reduction was not because
a total lack of surface NKG2D, due to the flow cytometry
analysis did not reveal the presence of more than a peak
in the histograms (Figure 4). We cannot discard the possi-
bility that the reduction in the number of NKG2D-
expressing cells could be attributed to cell death. In this
study we did not examine apoptosis in NK or T cells, and
we also did not look for sMICA bound to the NKG2D
receptor; therefore, we cannot know if a sMICA-induced
apoptosis mechanism in immune cells exists in patients
with cervical cancer and precursor lesions. The above phe-
nomenon has been reported with non-classical HLA mol-
ecules, such as HLA-G, which has multiple
immunoregulatory properties, mainly exemplified in the
abrogation of maternal NK cell activity [58]. This mole-
cule is expressed not only as a cell surface molecule, but
also as a soluble form which has been found in sera from
patients undergoing different malignancies [59-61]. Inter-
estingly, soluble isoforms of HLA-G have shown to trigger
in vitro apoptosis in both activated CD8+ cytotoxic NK and
T cells through a Fas/FasL mechanism [62,63]. In conse-
quence, this immunoregulatory role used by secreted
forms of HLA-G could represent an additional mechanism
by which tumors avoid the immune surveillance. There-
fore, it will be interesting to investigate if soluble HLA-G
is present in cervical cancer patients and especially, to
examine if serum HLA-G and MICA altogether are able to
deliver a death signal in immune cells.
Finally, the results derived from the multivariate regres-
sion analysis statistically show that an increase in sMICA
level may be associated with progression to invasive can-
cer; while an increase of NKG2D-expressing T cells could
be negatively correlated with cancer progression. We did
not find any significant correlation when we extended the
same analysis to NKG2D-expressing NK cells. Thus, it will
be interesting to design functional experiments to test
whether T cells are being affected by sMICA, even more, it
will be necessary to study separately CD4+ and CD8+ T
cells to discern their actual correlation with sMICA.
Conclusion
Our study reveals for the first time that sMICA is elevated
in patients with cervical cancer and precursor lesions. We
also demonstrated a reduced number of NKG2D-express-
Table 3: Multivariate regression analysis of sMICA and NKG2D-expressing T cells acting in concert in the progression of the lesion
Regression coefficients Standardized 
coefficient
95% C.I. for B
B SEM for B Beta t Sig. Lower limit Upper limit
Constant 2.417 0.532 4.544 0.000 1.336 3.497
Log10sMICA 0.314 0.128 0.330 2.460 0.019 0.055 0.574
% NKG2D-
expressing T 
cells
-0.057 0.015 -0.492 -3.667 0.001 -0.088 -0.025
B: regression coefficient in the equation which predicts the grade of the lesion considering to both sMICA and NKG2D expression as independent 
variables; SEM for B: standard error for the regression coefficients; Beta: standardized regression coefficient which determines the actual weight 
of the regression coefficient if all variables are expressed in standard units; t: t-test value for the regression coefficient; sig: p value (R2 = 0.467; p 
< 0.001).BMC Cancer 2008, 8:16 http://www.biomedcentral.com/1471-2407/8/16
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ing NK and T cells in patient samples. Furthermore, a sig-
nificant correlation between sMICA and NKG2D
expression was found in T cells, but not in NK cells. If con-
firmed that sMICA is directly contributing to the immune
evasion present in patients with cancer, targeting specific
proteases involved in MICA shedding from cell surfaces or
directly blocking sMICA in circulation could be a clini-
cally important strategy to boost the anti-tumor response
against cervical cancer.
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